Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joyce Frey-Vasconcells joins Aastrom SAB

This article was originally published in Scrip

Executive Summary

Aastrom Biosciences, a company developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe chronic cardiovascular diseases, has appointed Dr Joyce Frey-Vasconcells to its scientific advisory board. Dr Frey-Vasconcells is founder and president of Frey-Vasconcells Consulting and previously served as a regulatory consultant for Pharmanet. Prior to that, she spent more than 12 years at the FDA as deputy director, Office of Cellular, Tissue and Gene Therapies with the Center for Biologics Evaluation and Research.

You may also be interested in...



Iron off the tee as Takeda rolls out Rienso in EU

Takeda has launched Rienso (ferumoxytol), a new option for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) in the UK, after having been granted marketing authorization by the European Commission in June. This is the start of the product’s European roll out.

Joyce Frey-Vasconcells joins Aastrom SAB

Aastrom Biosciences, a company developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe chronic cardiovascular diseases, has appointed Dr Joyce Frey-Vasconcells to its scientific advisory board. Dr Frey-Vasconcells is founder and president of Frey-Vasconcells Consulting and previously served as a regulatory consultant for Pharmanet. Prior to that, she spent more than 12 years at the FDA as deputy director, Office of Cellular, Tissue and Gene Therapies with the Center for Biologics Evaluation and Research.

Itin, Chiswell and Davis recruited to Kymab board

Kymab, a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs has appointed Christian Itin, David Chiswell and Richard Davis to its board as non-executive directors. Dr Itin was recently appointed CEO and chair of the board at Cytos Biotechnology, having previously served as Micromet's president and CEO. Dr Chiswell currently serves as chair of Nabriva Therapeutics and Albireo Pharma and previously served as CEO of Nabriva Therapeutics.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel